LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with...
treatment News
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, was...
PHILADELPHIA, PA – Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced top line results from its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in 99 patients with newly diagnosed glioblastoma (ndGBM). Glioblastoma is a highly aggressive brain cancer with an average life...
BOSTON, Mass. — Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR-T cell therapy, in two oral sessions at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The data underscore CTD402’s potential...
WASHINGTON, DC – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital. “This is the first medicine that has been developed to specifically...
NEW YORK, NY — IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer. Cellular therapies, particularly chimeric antigen...
NEW YORK, NY — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma (GBM). The prior results were presented at the...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector...
CAMBRIDGE, Mass. — Incendia Therapeutics, a biotechnology company focused on disrupting the tumor microenvironment (TME) to improve cancer outcomes, today announced that it will present two posters at the International Thymic Malignancy Interest Group Annual Meeting to be held in Milan, Italy, October 2-4, 2025. Both posters disclose clinical results...
PLANEGG, Germany & MUNICH & WILMINGTON, Del. – Incyte (NASDAQ:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment...